The Ontario Superior Court of Justice has approved three opioid class-action settlements worth a combined $29.3 million, together with a pooled compensation plan and payments to class counsel and the litigation funder.
In Gebien v. Apotex Inc., 2026 ONSC 5428, released October 1, 2026, Justice E.M. Morgan found the agreements fair, reasonable and in the class’s best interests. The approval concerns settlements with Purdue Canada, Valeant/Bausch and Mylan, not a settlement with Apotex or a resolution of the claims against every defendant named in the lawsuit.
The decision approves negotiated compromises rather than making trial findings that the settling companies were liable. It also does not promise each claimant a fixed payment: eligibility, supporting documents, deductions and the number and severity of approved claims will affect compensation.
Three agreements, one fund
Purdue Pharma Inc. and Purdue Frederick Inc., described together as Purdue Canada, agreed to pay $28.5 million. The agreement with Valeant Canada LP, Valeant Canada S.E.C. and Bausch Health Companies Inc. contributes $600,000. Mylan Pharmaceuticals ULC contributes $200,000.
The court had certified the action against the settling defendants and approved hearing notices on February 23, 2026. No class members opted out by the deadline, and the only potential objector withdrew the objection after counsel explained the settlement.
The settlement classes encompass people in Canada prescribed or consuming the relevant manufacturers’ products, their heirs and qualifying family-law claimants, subject to exclusions. The reasons expressly exclude recovery by members of certain other class actions with similar claims.
This is separate from an earlier $20 million OxyContin and OxyNeo settlement covering people prescribed and ingesting those products between January 1, 1996 and February 28, 2017. The new Purdue settlement includes people who consumed those drugs after that earlier class period. These overlapping proceedings make the applicable product, period and exclusions important; the approval does not establish that every opioid user qualifies.
Why the court accepted the compromises
Justice Morgan identified substantial obstacles to continuing the litigation. Plaintiffs would have to establish causation in a class proceeding, then potentially prove individual harm and how responsibility should be divided between defendants. Even a successful failure-to-warn claim would face regulatory defences based on Health Canada’s approval of the drugs and required warnings.
The possibility of insolvency added another risk. Related Purdue entities had entered U.S. bankruptcy proceedings, and the judge considered the danger that meaningful recovery could become unavailable by the end of a lengthy trial and individual-claims process.
Valeant and Mylan presented an additional problem: counsel had been unable to identify representative plaintiffs with documented claims against them. Applying the requirement for a representative plaintiff with a claim against each defendant, the judge found that this could threaten the viability of those claims altogether.
Pooling the settlements gives eligible Valeant and Mylan claimants access to compensation measured by their harm rather than limiting them to their manufacturer’s smaller contribution. The court considered that a significant benefit of the agreements.
Payments depend on eligibility and available money
Under the approved protocol, class members who were prescribed and consumed the relevant products may qualify for a common-experience payment of up to $1,000. Qualifying family-law class members may receive up to $250. Those ceilings are not guaranteed awards.
After counsel, funder and other expenses are deducted, no more than $2 million is allocated to those common-experience payments. If the claims exceed that pool, the payments will be reduced proportionately.
The remaining funds are allocated to documented harm awards at three levels. Every award within a level has the same value; Level 2 pays twice Level 1, and Level 3 pays three times Level 1. The reasons do not specify fixed dollar amounts for those awards. The protocol also provides a Level 1 award for qualifying family-law claimants in specified fatal-overdose or suicide circumstances.
The claims process is paper-based, without oral testimony or interviews. It will not require examination of pre-existing conditions, other addiction issues or mental-health history. Claimants seeking harm awards receive six additional months after the initial claims deadline to provide supporting documents, with counsel assisting them and claims undergoing an initial review followed by administrator review.
At the time of the ruling, short- and long-form notices still had to be drafted and submitted for court approval before the protocol began. The reasons do not set a calendar date for submitting claims. June 30, 2027 is instead the cutoff for other settlements that could potentially join the distribution arrangement at the court’s direction.
Legal fees and funding costs reduce the gross total
The court approved $8,358,585.71 for class counsel: $7,325,000 in fees, $952,250 in tax and $81,335.71 in disbursements. It separately approved $5,346,783.50 for litigation funder Omni Bridgeway under the funding agreement.
Justice Morgan assessed counsel’s risk, the litigation’s complexity and the result achieved. Counsel requested 25 per cent of the settlement value rather than the 30 per cent contemplated by the retainers, leaving an additional $1,465,000 for the class.
Administration and other relevant expenses also come out of the fund. The $29.3 million headline figure is therefore the combined gross settlement amount, not the amount ultimately available for individual payments.
